Genital Herpes

Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection

Conditions:   Genital Herpes;   HSV-2 Infection
Interventions:   Biological: GEN-003;   Biological: Matrix-M2;   Other: 0.9% normal saline
Sponsor:   Genocea Biosciences, Inc.
Not yet recruiting - verified May 2017

The VIBLOK SAfety and perFormancE Trial

Conditions:   HSV-2 Infection;   Genital Herpes
Intervention:   Device: VIBLOK barrier cream
Sponsors:   CLJI Worldwide;   Applied Clinical Services BV;   UMC Utrecht;   University of Rotterdam, The Netherlands;   University of Washington;   EB FlevoResearch BV;   PreCare Trial & Recruitment B.V.
Recruiting - verified March 2017

Comparative Effectiveness of Treatment Options for Genital Herpes Infection to Reduce Adverse Pregnancy Outcomes

Conditions:   HSV-2 Infection;   PreTerm Birth;   Pregnancy Complications
Sponsors:   Kaiser Permanente;   Patient-Centered Outcomes Research Institute
Recruiting - verified March 2017

Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity

Condition:   Genital Herpes Simplex Type 2
Intervention:   Biological: Observational
Sponsor:   Genocea Biosciences, Inc.
Active, not recruiting - verified December 2016

Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food

Conditions:   Herpes Genitalis;   Herpes Zoster
Interventions:   Drug: ASP2151;   Drug: Placebo
Sponsor:   Astellas Pharma Europe Ltd.
Completed - verified July 2016

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

Condition:   Herpes Genitalis
Interventions:   Biological: VCL-HB01;   Other: Phosphate-buffered saline
Sponsor:   Vical
Active, not recruiting - verified April 2017

Evaluating New Formulation of Therapeutic HSV-2 Vaccine

Condition:   Genital Herpes Simplex Type 2
Interventions:   Biological: Matrix-M2;   Biological: GEN-003;   Drug: Placebo
Sponsor:   Genocea Biosciences, Inc.
Active, not recruiting - verified August 2016

Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study

Condition:   Genital Herpes Simplex Type 2
Interventions:   Biological: Matrix-M2 Adjuvant;   Biological: GEN-003 Vaccine
Sponsor:   Genocea Biosciences, Inc.
Completed - verified July 2016

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

Condition:   Genital Herpes Simplex Type 2
Interventions:   Biological: VCL-HB01;   Biological: VCL-HM01;   Biological: PBS
Sponsor:   Vical
Completed - verified July 2016

Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection

Conditions:   Genital Herpes;   Herpes Simplex Virus;   Herpes Simplex Virus Vaccines;   HSV Vaccines;   Herpesvirus Vaccines
Intervention:   Biological: HSV529
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Sanofi Pasteur, a Sanofi Company
Completed - verified March 6, 2017

Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes

Condition:   Genital Herpes
Interventions:   Drug: AIC316;   Drug: Valacyclovir
Sponsors:   AiCuris Anti-infective Cures GmbH;   Medpace, Inc.
Terminated - verified September 2016

Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)

Condition:   Genital Herpes
Intervention:   Drug: Valaciclovir Hydrochloride.
Sponsor:   GlaxoSmithKline
Completed - verified May 2017

Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

Condition:   Genital Herpes
Interventions:   Drug: valacyclovir;   Drug: Valacyclovir
Sponsors:   University of Washington;   GlaxoSmithKline
Completed - verified March 2017

Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?

Conditions:   HIV Infection;   Herpes Simplex Type II;   HIV Infections
Interventions:   Drug: valacyclovir;   Drug: Placebo
Sponsors:   University Health Network, Toronto;   CIHR Canadian HIV Trials Network
Active, not recruiting - verified May 2016

A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation

Condition:   Genital Herpes
Intervention:   Drug: acyclovir
Sponsors:   University of Washington;   National Institutes of Health (NIH)
Completed - verified March 2017

Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease

Condition:   Herpes Simplex
Interventions:   Biological: Herpes simplex candidate vaccine- adjuvanted GSK208141;   Biological: Placebo injection
Sponsor:   GlaxoSmithKline
Completed - verified September 2016

Effect of HSV-2 Suppressive Therapy on Sexual Behavior

Condition:   Genital Herpes
Interventions:   Drug: acyclovir;   Drug: acyclovir
Sponsors:   University of Washington;   National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting - verified October 2016

VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2

Condition:   Herpes Labialis
Intervention:   Drug: valacyclovir
Sponsor:   GlaxoSmithKline
Completed - verified December 2016

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

Condition:   Infections, Herpesviridae
Intervention:   Drug: Valaciclovir
Sponsor:   GlaxoSmithKline
Completed - verified December 2016

A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons

Conditions:   HIV Infection;   Genital Herpes
Intervention:   Drug: valacyclovir hydrochloride
Sponsor:   GlaxoSmithKline
Terminated - verified March 2017

HerpeVac Trial for Young Women

Condition:   Herpes Simplex Infection
Interventions:   Biological: HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine;   Biological: Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine
Sponsor:   GlaxoSmithKline
Completed - verified March 2013

Refine Your Search Advanced Search